T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease.

ABSTRACT:

Background

Vaccination is a promising strategy to protect vulnerable groups like immunocompromised inflammatory bowel disease [IBD] patients from an infection with SARS-CoV-2. These patients may have lower immune responses. Little is known about the cellular and humoral immune response after a SARS-CoV-2 vaccination in IBD patients.

Methods

Totals of 28 patients with IBD and 27 age- and sex-matched healthy controls were recruited at Jena University Hospital. Blood samples were taken before, after the first, and in a subgroup of 11 patients after second dose of a SARS-CoV-2 vaccination. Cellular immune response, including IFN-γ and TNF-α response and antibody titres, were analysed.

Results

Overall, 71.4% of the IBD patients and 85.2% of the controls showed levels of an

SUBMITTER: Reuken PA 

PROVIDER: S-EPMC8385945 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature